0001104659-26-058703
SEC filingProgress toward profitability amid oncology focus transition, with revenue surging 62% to $12.3M on LOQTORZI volume and losses narrowing on cost leverage, though cash burn accelerated to -$57.9M from working capital needs.
Revenue rose 62.0% year-over-year to $12.3 million in Q1 FY2026 from $7.6 million, primarily from expanded LOQTORZI volume following NCCN guideline inclusion, enabling greater market penetration in the oncology segment. This topline acceleration underscores the strategic pivot to high-value immuno-oncology assets post-biosimilar divestiture, positioning Coherus for sustained growth as LOQTORZI evaluation advances through ongoing clinical studies by the company and partners.
Gross profit climbed 71.8% to $8.5 million, yielding a 69.0% gross margin versus prior-year levels. The margin expansion reflects efficiencies in scaled LOQTORZI production, where fixed manufacturing costs diluted over higher volumes despite increased COGS from sales ramp. This operational leverage demonstrates the benefits of focusing resources on fewer, higher-margin products after exiting lower-margin biosimilars.
Operating loss narrowed 20.4% to -$36.2 million from -$45.4 million, with operating margin at -293.7%. The improvement stems from revenue growth outpacing expense growth, supported by expected reductions in fixed R&D from lower manufacturing development and headcount, as well as lower SG&A from decreased operating costs and staffing post-divestiture. Management notes that total R&D, including external clinical costs, will depend on data readouts and portfolio prioritization, signaling disciplined capital allocation amid ongoing innovation.
Net loss improved 32.2% to -$38.3 million from -$56.6 million, with diluted EPS at -$0.28 versus -$0.49. Favorable other income dynamics, absent prior-year charges, contributed alongside topline gains and opex efficiencies. This trajectory highlights divestiture-enabled cost leverage, though R&D intensity in oncology pipeline development sustains losses while building long-term value.
Net cash used in operating activities widened to -$57.9 million from -$25.8 million. Prior-period cash flows from discontinued operations reflected inventory builds and derivative adjustments, while current period working capital needs—tied to receivables and inventory for continuing operations, including UDENYCA divestiture-related obligations—drove higher burn. Cash in excess of requirements remains invested for liquidity and preservation, as the company anticipates future capital needs to fund operations and pipeline advancement.